Physician profile
Saranapoom Klomjit
NPI 1396186003
$1,693.34
in general payments reported to CMS, 2019-2025
25 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2021: $82.56 · 2022: $58.96 · 2023: $78.60 · 2024: $515 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,410.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $218.43 | 2025 | |
| Abbott Laboratories | $193.97 | 2023-2025 | Navitor, Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $186.89 | 2019-2025 | Lifevest |
| W. L. Gore & Associates, INC. | $147.84 | 2024 | Gore Cardioform Septal Occluder |
| Medtronic, INC. | $141.52 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $121.21 | 2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $106.83 | 2024 | Sapien 3 Ultra Resilia |
| Novo Nordisk INC | $81.01 | 2024 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.51 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $45.46 | 2024-2025 | Camzyos |
| Amgen INC. | $42.47 | 2024-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $39.95 | 2019 | |
| Pfizer INC. | $38.87 | 2025 | |
| Merck Sharp & Dohme LLC | $38.56 | 2025 | Verquvo |
| Abiomed | $37.06 | 2024-2025 | Impella |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.24 | 2024-2025 | |
| Lilly USA, LLC | $23.48 | 2025 | Mounjaro, Zepbound |
| Kiniksa Pharmaceuticals International, Plc | $22.69 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $22.67 | 2025 | Inspire |
| Cvrx, INC. | $18.34 | 2024 | Barostim Neo System |
| Esperion Therapeutics, INC. | $17.78 | 2025 | Nexletol |
| Philips North America LLC | $15.97 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Janssen Pharmaceuticals, INC | $15.83 | 2024 | Xarelto |
| Scpharmaceuticals INC. | $15.78 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saranapoom Klomjit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.